• Home
  • Tofacitinib 5mg
  • Tofacitinib 5mg

Tofacitinib 5mg

52188

Tofacitinib is used for moderate to severe rheumatoid arthritis, psoriatic arthritis, and some forms of axial arthritis when other treatments have not worked well enough or are not suitable.

It is also used for moderately to severely active ulcerative colitis and for some children with polyarticular juvenile idiopathic arthritis.

Usual adult dose range: 5mg to 10mg twice daily for immediate-release tablets, or 11mg to 22mg once daily for extended-release tablets, depending on the autoimmune condition.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.